Company Revenue

The company grew 20% in the second quarter of 2024 driven by an expanding portfolio and active surgeon base....

The company continued its high-growth performance but initiated a restructuring to lay the foundation for durable growth....

The company's headwinds from the LimaCorporate integration peaked in the second quarter and should mitigate in the second half of...

The company grew in the mid-single digits during the second quarter of 2024 as it builds toward sustainable above-market growth....

The company grew in the mid-single digits on a constant currency basis and expanded its technology options for surgeons....

The company continued its strong performance in the second quarter amid integration efforts and raised 2024 pro forma guidance....

The company grew 25% in the second quarter of 2024, taking people and market share from spine's incumbent players....

The company's MACI sales grew over 20% in the second quarter of 2024 as biopsy rates and conversions ramp up...

The company's orthopedic sale grew in the mid single digits during the second quarter as its transformation plan shows results....

The company's sales declined in the low single digits in the second quarter of 2024 amid a bevy of ongoing...